Bringing Retinal Health into focus
![](https://visgenx.wpenginepowered.com/wp-content/uploads/2022/06/bg-hero-image@2x.png)
![](https://visgenx.wpenginepowered.com/wp-content/uploads/2022/06/bg-text-block-image-1.png)
ELOVL2 Gene Therapy for Dry AMD »
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues.
Dry-AMD Overview
progressive disease
Resulting in loss of photoreceptor cells and visual acuity
Such as driving, cooking, reading, and facial recognition
There are no approved therapies
![](https://visgenx.wpenginepowered.com/wp-content/uploads/2022/06/bg-aging-retina.png)
![](https://visgenx.wpenginepowered.com/wp-content/uploads/2022/06/bg-young-retina.png)
Age-Related Macular Degeneration and Geographic Atrophy»
We believe dysregulation of lipid (fatty acid) bio-synthesis resulting from declining expression of a gene known as ELOVL2 underlies Dry Macular Degeneration.
Innovation in Focus.
We are scientists, entrepreneurs and drug developers with a goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.
![](https://visgenx.wpenginepowered.com/wp-content/uploads/2022/06/bg-cta.png)
Visgenx in Focus.
Our goal is to develop therapeutics that slow or halt cellular senescense in macular degeneration and other age-related disorders by “turning back the clock” to a more youthful level of ELOVL2 expression.